20/20 Biolabs, Inc. is a biotechnology company specializing in the development and commercialization of AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. Its primary offerings fall under the OneTest brand, including OneTest for Cancer, a multi-cancer early detection (MCED) blood test that analyzes tumor-associated protein biomarkers to identify cancers such as lung, pancreatic, ovarian, and liver at treatable stages, and OneTest for Longevity, which measures inflammatory biomarkers linked to conditions like heart disease, dementia, diabetes, and mental health issues, with a launch anticipated in early 2026. These tests utilize convenient at-home upper arm blood collection devices and are processed in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland. 20/20 Biolabs also operates the Clinical Laboratory Innovation Accelerator (CLIAx), the first shared CLIA lab supporting overseas diagnostics startups in launching U.S. tests without independent infrastructure costs. Founded in 2000, the firm employs 24 people in the diagnostics and research industry within healthcare, led by CEO Jonathan Cohen, and recently debuted on Nasdaq to scale growth and pursue strategic acquisitions focused on prevention over treatment.